Oramed Pharmaceuticals Management
Management criteria checks 3/4
Oramed Pharmaceuticals' CEO is Nadav Kidron, appointed in Mar 2006, has a tenure of 18.17 years. total yearly compensation is $1.66M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 2.88% of the company’s shares, worth ₪10.12M. The average tenure of the management team and the board of directors is 11.4 years and 7.7 years respectively.
Key information
Nadav Kidron
Chief executive officer
US$1.7m
Total compensation
CEO salary percentage | 27.9% |
CEO tenure | 18.2yrs |
CEO ownership | 2.9% |
Management average tenure | 11.4yrs |
Board average tenure | 7.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$463k | US$6m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$20m |
Mar 31 2023 | n/a | n/a | -US$30m |
Dec 31 2022 | US$7m | US$491k | -US$37m |
Sep 30 2022 | n/a | n/a | -US$46m |
Jun 30 2022 | n/a | n/a | -US$46m |
Mar 31 2022 | n/a | n/a | -US$40m |
Dec 31 2021 | n/a | n/a | -US$35m |
Nov 30 2021 | n/a | n/a | -US$25m |
Aug 31 2021 | US$4m | US$466k | -US$22m |
May 31 2021 | n/a | n/a | -US$18m |
Feb 28 2021 | n/a | n/a | -US$15m |
Dec 31 2020 | n/a | n/a | -US$22m |
Nov 30 2020 | n/a | n/a | -US$15m |
Aug 31 2020 | US$2m | US$439k | -US$12m |
May 31 2020 | n/a | n/a | -US$11m |
Feb 29 2020 | n/a | n/a | -US$13m |
Nov 30 2019 | n/a | n/a | -US$13m |
Aug 31 2019 | US$2m | US$419k | -US$14m |
May 31 2019 | n/a | n/a | -US$15m |
Feb 28 2019 | n/a | n/a | -US$15m |
Nov 30 2018 | n/a | n/a | -US$14m |
Aug 31 2018 | US$2m | US$436k | -US$13m |
May 31 2018 | n/a | n/a | -US$12m |
Feb 28 2018 | n/a | n/a | -US$10m |
Nov 30 2017 | n/a | n/a | -US$10m |
Aug 31 2017 | US$1m | US$400k | -US$10m |
Compensation vs Market: Nadav's total compensation ($USD1.66M) is above average for companies of similar size in the IL market ($USD434.82K).
Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.
CEO
Nadav Kidron (49 yo)
18.2yrs
Tenure
US$1,659,222
Compensation
Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 18.2yrs | US$1.66m | 2.88% $ 10.1m | |
CFO & Treasurer | 2.8yrs | US$536.71k | 0.22% $ 788.9k | |
Chief Scientific Officer & Director | 18.2yrs | US$1.11m | 0.21% $ 748.0k | |
Chief Operating & Business Officer | 4.7yrs | US$1.28m | 0.43% $ 1.5m |
11.4yrs
Average Tenure
51yo
Average Age
Experienced Management: ORMP's management team is seasoned and experienced (11.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 18.2yrs | US$1.66m | 2.88% $ 10.1m | |
Chief Scientific Officer & Director | 18.2yrs | US$1.11m | 0.21% $ 748.0k | |
Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
Member of Scientific Advisory Board | 17.3yrs | no data | no data | |
Member of Scientific Advisory Board | 7.5yrs | US$20.00k | no data | |
Member of Scientific Advisory Board | 15.8yrs | no data | no data | |
Member of Scientific Advisory Board | 4.4yrs | no data | no data | |
Independent Director | 16.6yrs | US$112.28k | 0.068% $ 240.4k | |
Member of the Scientific Advisory Board | 7.8yrs | no data | no data | |
Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
Independent Director | 4.4yrs | US$127.28k | 0.064% $ 224.1k | |
Member of Scientific Advisory Board | 4.3yrs | no data | no data |
7.7yrs
Average Tenure
69yo
Average Age
Experienced Board: ORMP's board of directors are considered experienced (7.7 years average tenure).